Articles

P1.09 RASSF4 functions as a tumor suppressor in Multiple Myeloma

BJH - volume 7, issue Abstract Book BHS, january 2016

E. De Smedt , K. Maes , S. Verhulst , C. Heirman , A. Maes , K. Breckpot , L. Van Grunsven , J. Moreaux , E. De Bruyne

Read more

P1.13 Blocking S100A9 interactions in the Multiple Myeloma bone marrow environment reduces angiogenesis and tumor growth

BJH - volume 7, issue Abstract Book BHS, january 2016

E. Van Valckenborgh PhD, K. De Veirman , H. De Raeve MD, PhD, K. Maes , E. De Bruyne , E. Menu , K. Vanderkerken PhD

Read more

P1.02 In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma

BJH - volume 6, issue Abstract Book BHS, january 2015

K. Maes , E. De Smedt , A. Kassambara , D. Hose , A. Seckinger , E. Van Valckenborgh PhD, E. Menu , B. Klein , K. Vanderkerken PhD, J. Moreaux , E. De Bruyne

Read more

O.5 In vivo gene expression profiling in the murine 5T33MM model identifies epigenetic-regulated genes predictive for prognosis and drug-sensitivity

BJH - volume 5, issue Abstract Book BHS, january 2014

K. Maes , E. De Smedt , D. Hose , E. Van Valckenborgh PhD, E. Menu , B. Klein , K. Vanderkerken PhD, J. Moreaux , E. De Bruyne

Read more

P.05 The Combination of Decitabine and the Histone Deacetylase Inhibitor JNJ-26481585 Has Synergistic Anti-Myeloma Activity

BJH - 2013, issue BHS Abstractbook, january 2013

K. Maes , M. Lemaire , E. De Smedt , E. Menu , E. Van Valckenborgh PhD, K. Vanderkerken PhD, E. De Bruyne

Read more